Atai
Atai Life Sciences NV (ATAI) clinical-stage biopharmaceutical firm seeking to revolutionize the way we treat mental health disorders. The company has spent years developing psychedelic therapies based on substances such as psychedelic substances like Psilocybin, R-ketamine, Ibogaine, DMT, and MDMA derivatives.
Not only is Atai the largest player in this market, valued at over $265 million but it’s also backed by prominent tech figures such as Peter Thiel. The company is also one of the few to have a partnership with a major pharmaceutical company. It’s working with Japanese drugmaker Otsuka to develop a depression treatment based on r-ketamine.
The stock has dropped 90% since its listing in 2021, which highlights how precarious this industry is.
Contemporary art has outperformed the S&P 500 by 131% for the past 26 years. Join the exclusive platform to invest in million-dollar works by artists like Banksy, Basquiat, and more. Get started today and diversify your portfolio with art.
Learn MoreCompass
Initially launched as a not-for-profit in 2015 to research the use of psychedelic drugs on anxiety and depression, Compass Pathways pivoted to for-profit in 2016 and listed on the NASDAQ in 2020.
Since then, the stock has lost 72% of its market value. However, its drug development pipeline is still moving forward. Compass successfully completed its phase 2 study evaluating COMP360 in treatment-resistant depression. This was the largest clinical trial in the history of psilocybin therapy. Now the company is working on similar studies focused on post-traumatic stress disorder (PTSD) treatments.
Some of Compass’ research and development is funded by Atai, which owns a minority stake in the firm. This base of investors and success at clinical trials makes Compass an interesting opportunity for investors.
CYBIN
Toronto-based Cybin has completed over 140 preclinical trials of its various psychedelic treatments for mental health disorders. One of its leading candidates is a drug labeled CYB001, which is designed to potentially treat major depressive disorder.
Cybin stock is down 75% over the past year, which means its market value is smaller than its rivals mentioned above. Investors should consider this a penny stock in the risky world of psychedelics.
Sponsored
Meet Your Retirement Goals Effortlessly
The road to retirement may seem long, but with WiserAdvisor, you can find a trusted partner to guide you every step of the way
Wiseradvisor matches you with vetted financial advisors that offer personalized advice to help you to make the right choices, invest wisely, and secure the retirement you've always dreamed of. Start planning early, and get your retirement mapped out today.
